Compare Organon & Co. Common Stock (OGN) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vanguard Total World Stock Index Fund ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Vanguard Total World Stock Index Fund ETF trades at $157.28 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 28.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vanguard Total World Stock Index Fund ETF for 54 Days on average.
| OGN | VT | |
|---|---|---|
Market Cap | $3.61B | $101.70B |
Volume | 1,808,049 | 3,791,840 |
Sector | Health | Broad Market / Factor |
52-Week High | $13.81 | $162.39 |
52-Week Low | $5.70 | $134.19 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Vanguard Total World Stock ETF (VT) trades at $159.76, showing modest daily gains of 0.16% with neutral technical indicators. The ETF maintains broad global diversification across 9,773 stocks with a low 0.06% expense ratio. Recent news highlights VT's strong five-year performance compared to international-focused peers, though some competitors offer lower fees. Technical analysis shows the ETF trading near pivot point resistance at $160 with support at $159.
VT provides comprehensive global equity exposure but faces fee competition from alternatives like SPDW. The ETF's broad diversification minimizes country-specific risks while capturing global growth. Key risks include expense ratio pressure and emerging market volatility. Analyst sentiment remains positive for long-term investors seeking one-stop global diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
